145 related articles for article (PubMed ID: 31339816)
1. Estimates of Testing for Latent Tuberculosis Infection and Cost, United States, 2013.
Marks SM; Woodruff RY; Owusu-Edusei K; Asay GRB; Hill AN
Public Health Rep; 2019; 134(5):522-527. PubMed ID: 31339816
[TBL] [Abstract][Full Text] [Related]
2. A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program.
Wingate LT; Coleman MS; de la Motte Hurst C; Semple M; Zhou W; Cetron MS; Painter JA
BMC Public Health; 2015 Dec; 15():1201. PubMed ID: 26627449
[TBL] [Abstract][Full Text] [Related]
3. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
Haukaas FS; Arnesen TM; Winje BA; Aas E
Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
[TBL] [Abstract][Full Text] [Related]
4. A five-year analysis of latent tuberculosis infection in Queensland, 2016-2020.
Dalmau M; Coulter C; O'Connor B; Robson J; Field E; Lambert S
Commun Dis Intell (2018); 2023 Nov; 47():. PubMed ID: 37968069
[TBL] [Abstract][Full Text] [Related]
5. Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands.
Erkens CG; Dinmohamed AG; Kamphorst M; Toumanian S; van Nispen-Dobrescu R; Alink M; Oudshoorn N; Mensen M; van den Hof S; Borgdorff M; Verver S
Int J Tuberc Lung Dis; 2014 Apr; 18(4):413-20. PubMed ID: 24670695
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis.
Doan TN; Eisen DP; Rose MT; Slack A; Stearnes G; McBryde ES
PLoS One; 2017; 12(11):e0188631. PubMed ID: 29182688
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups.
Auguste P; Tsertsvadze A; Court R; Pink J
Tuberculosis (Edinb); 2016 Jul; 99():81-91. PubMed ID: 27450009
[TBL] [Abstract][Full Text] [Related]
8. Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis - End of the road?
Mwaba P; Chakaya JM; Petersen E; Wejse C; Zumla A; Kapata N
Int J Infect Dis; 2020 Mar; 92S():S69-S71. PubMed ID: 32119979
[TBL] [Abstract][Full Text] [Related]
9. Methods Used in Economic Evaluations of Tuberculin Skin Tests and Interferon Gamma Release Assays for the Screening of Latent Tuberculosis Infection: A Systematic Review.
Koufopoulou M; Sutton AJ; Breheny K; Diwakar L
Value Health; 2016; 19(2):267-76. PubMed ID: 27021762
[TBL] [Abstract][Full Text] [Related]
10. Latent Tuberculosis Infection Testing Strategies for HIV-Positive Individuals in Hong Kong.
Wong NS; Chan KCW; Wong BCK; Leung CC; Chan WK; Lin AWC; Lui GCY; Mitchell KM; Lee SS
JAMA Netw Open; 2019 Sep; 2(9):e1910960. PubMed ID: 31490541
[TBL] [Abstract][Full Text] [Related]
11. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions.
Kleinert S; Tony HP; Krueger K; Detert J; Mielke F; Rockwitz K; Schwenke R; Burmester GR; Diel R; Feuchtenberger M; Kneitz C
Ann Rheum Dis; 2012 Nov; 71(11):1791-5. PubMed ID: 22586160
[TBL] [Abstract][Full Text] [Related]
12. The use of an interferon-gamma release assay to screen for pediatric latent tuberculosis infection in the eastern region of the Emirate of Abu Dhabi.
Al Mekaini LA; Al Jabri ON; Narchi H; Kamal SM; Mabrook A; Al Kuwaiti MM; Sheek-Hussein MM; Souid AK; Alsuwaidi AR
Int J Infect Dis; 2014 Jun; 23():4-7. PubMed ID: 24657274
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study.
Klautau GB; da Mota NVF; Salles MJC; Burattini MN; Rodrigues DS
BMC Infect Dis; 2018 Nov; 18(1):585. PubMed ID: 30453903
[TBL] [Abstract][Full Text] [Related]
14. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
Cui X; Gao L; Cao B
Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
[TBL] [Abstract][Full Text] [Related]
15. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.
Campbell JR; Johnston JC; Ronald LA; Sadatsafavi M; Balshaw RF; Cook VJ; Levin A; Marra F
Am J Kidney Dis; 2019 Jan; 73(1):39-50. PubMed ID: 30269868
[TBL] [Abstract][Full Text] [Related]
16. Position statement on interferon-γ release assays for the detection of latent tuberculosis infection.
Bastian I; Coulter C;
Commun Dis Intell Q Rep; 2017 Dec; 41(4):E322-E336. PubMed ID: 29864386
[TBL] [Abstract][Full Text] [Related]
17. Risk of Occupational Latent Tuberculosis Infection among Health Personnel Measured by Interferon-Gamma Release Assays in Low Incidence Countries-A Systematic Review and Meta-Analysis.
Peters C; Kozak A; Nienhaus A; Schablon A
Int J Environ Res Public Health; 2020 Jan; 17(2):. PubMed ID: 31963207
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.
Hardy AB; Varma R; Collyns T; Moffitt SJ; Mullarkey C; Watson JP
Thorax; 2010 Feb; 65(2):178-80. PubMed ID: 19996345
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.
Campbell JR; Sasitharan T; Marra F
Appl Health Econ Health Policy; 2015 Aug; 13(4):325-40. PubMed ID: 26129810
[TBL] [Abstract][Full Text] [Related]
20. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Kahwati LC; Feltner C; Halpern M; Woodell CL; Boland E; Amick HR; Weber RP; Jonas DE
JAMA; 2016 Sep; 316(9):970-83. PubMed ID: 27599332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
